NO331674B1 - Farmasoytisk sammensetning omfattende nikotinreseptorantagonist for lindring eller forebygging av pulmonaer inflammatorisk sykdom - Google Patents
Farmasoytisk sammensetning omfattende nikotinreseptorantagonist for lindring eller forebygging av pulmonaer inflammatorisk sykdom Download PDFInfo
- Publication number
- NO331674B1 NO331674B1 NO20034185A NO20034185A NO331674B1 NO 331674 B1 NO331674 B1 NO 331674B1 NO 20034185 A NO20034185 A NO 20034185A NO 20034185 A NO20034185 A NO 20034185A NO 331674 B1 NO331674 B1 NO 331674B1
- Authority
- NO
- Norway
- Prior art keywords
- nicotine
- dmpp
- cells
- inflammatory
- agonists
- Prior art date
Links
- 229960002715 nicotine Drugs 0.000 title claims abstract description 86
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 86
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 83
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 17
- 230000002685 pulmonary effect Effects 0.000 title claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 230000002265 prevention Effects 0.000 title claims description 4
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims abstract description 34
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims abstract description 34
- 239000000556 agonist Substances 0.000 claims abstract description 31
- 208000006673 asthma Diseases 0.000 claims abstract description 30
- 208000029523 Interstitial Lung disease Diseases 0.000 claims abstract description 15
- 239000000181 nicotinic agonist Substances 0.000 claims abstract description 14
- 201000000306 sarcoidosis Diseases 0.000 claims abstract description 12
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims abstract description 11
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 7
- 229940123925 Nicotinic receptor agonist Drugs 0.000 claims abstract description 4
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims abstract description 4
- 206010035742 Pneumonitis Diseases 0.000 claims abstract description 4
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims abstract description 4
- MKGIQRNAGSSHRV-UHFFFAOYSA-N 1,1-dimethyl-4-phenylpiperazin-1-ium Chemical compound C1C[N+](C)(C)CCN1C1=CC=CC=C1 MKGIQRNAGSSHRV-UHFFFAOYSA-N 0.000 claims description 73
- NLPRAJRHRHZCQQ-UHFFFAOYSA-N Epibatidine Natural products C1=NC(Cl)=CC=C1C1C(N2)CCC2C1 NLPRAJRHRHZCQQ-UHFFFAOYSA-N 0.000 claims description 14
- NLPRAJRHRHZCQQ-IVZWLZJFSA-N epibatidine Chemical compound C1=NC(Cl)=CC=C1[C@@H]1[C@H](N2)CC[C@H]2C1 NLPRAJRHRHZCQQ-IVZWLZJFSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 239000003246 corticosteroid Substances 0.000 claims description 8
- 229960001334 corticosteroids Drugs 0.000 claims description 8
- 229940124630 bronchodilator Drugs 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 5
- 238000007912 intraperitoneal administration Methods 0.000 claims description 5
- 239000000168 bronchodilator agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 230000002590 anti-leukotriene effect Effects 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 59
- 206010061218 Inflammation Diseases 0.000 abstract description 18
- 230000004054 inflammatory process Effects 0.000 abstract description 18
- 208000019693 Lung disease Diseases 0.000 abstract description 17
- 229940044601 receptor agonist Drugs 0.000 abstract description 12
- 239000000018 receptor agonist Substances 0.000 abstract description 12
- 241001465754 Metazoa Species 0.000 abstract description 9
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 150000003431 steroids Chemical class 0.000 abstract description 4
- 230000014509 gene expression Effects 0.000 description 70
- 210000004027 cell Anatomy 0.000 description 57
- 238000011282 treatment Methods 0.000 description 52
- 108020004999 messenger RNA Proteins 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 27
- 241001134661 Saccharopolyspora rectivirgula Species 0.000 description 21
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 20
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 20
- 210000004072 lung Anatomy 0.000 description 18
- 239000000126 substance Substances 0.000 description 16
- 230000002757 inflammatory effect Effects 0.000 description 15
- 210000004698 lymphocyte Anatomy 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 108010035532 Collagen Proteins 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 12
- 102100040247 Tumor necrosis factor Human genes 0.000 description 12
- 210000001132 alveolar macrophage Anatomy 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 12
- 102100037850 Interferon gamma Human genes 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 231100000673 dose–response relationship Toxicity 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000003979 eosinophil Anatomy 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 8
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 235000019504 cigarettes Nutrition 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 230000003828 downregulation Effects 0.000 description 7
- 210000004969 inflammatory cell Anatomy 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 101000609767 Dromaius novaehollandiae Ovalbumin Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000779 smoke Substances 0.000 description 6
- 210000002469 basement membrane Anatomy 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000002327 eosinophilic effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 4
- 229960002525 mecamylamine Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 4
- 229960002329 methacholine Drugs 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 102100037611 Lysophospholipase Human genes 0.000 description 3
- 108010058864 Phospholipases A2 Proteins 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000036428 airway hyperreactivity Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 238000000586 desensitisation Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- -1 nicotine compound Chemical class 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000035939 Alveolitis allergic Diseases 0.000 description 2
- 108010045634 B7 Antigens Proteins 0.000 description 2
- 102000005738 B7 Antigens Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 208000027445 Farmer Lung Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 208000022195 farmer lung disease Diseases 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000004047 hyperresponsiveness Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108700025647 major vault Proteins 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- HBYHYLBZPLCIEE-UHFFFAOYSA-N 2,4-dinitro-6-propan-2-ylphenol Chemical compound CC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O HBYHYLBZPLCIEE-UHFFFAOYSA-N 0.000 description 1
- 101150008391 A1 gene Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229940122578 Acetylcholine receptor agonist Drugs 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101500024172 Homo sapiens Adrenomedullin Proteins 0.000 description 1
- 101000685668 Homo sapiens Bile acyl-CoA synthetase Proteins 0.000 description 1
- 101000715643 Homo sapiens Bile salt-activated lipase Proteins 0.000 description 1
- 101000735459 Homo sapiens Protein mono-ADP-ribosyltransferase PARP9 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001440840 Mikania micrantha Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000005248 Vocal Cord Paralysis Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 230000000682 bronchomotor Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 102000056810 human PARP9 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002341952A CA2341952A1 (en) | 2001-03-23 | 2001-03-23 | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| PCT/CA2002/000412 WO2002076434A2 (en) | 2001-03-23 | 2002-03-25 | Nicotinic receptor agonists for the treatment of inflammatory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20034185D0 NO20034185D0 (no) | 2003-09-19 |
| NO20034185L NO20034185L (no) | 2003-11-24 |
| NO331674B1 true NO331674B1 (no) | 2012-02-20 |
Family
ID=4168679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034185A NO331674B1 (no) | 2001-03-23 | 2003-09-19 | Farmasoytisk sammensetning omfattende nikotinreseptorantagonist for lindring eller forebygging av pulmonaer inflammatorisk sykdom |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7601720B2 (ja) |
| EP (1) | EP1370264B1 (ja) |
| JP (1) | JP4377586B2 (ja) |
| CN (1) | CN100528159C (ja) |
| AT (1) | ATE378051T1 (ja) |
| AU (1) | AU2002249023B2 (ja) |
| BR (1) | BR0208305A (ja) |
| CA (1) | CA2341952A1 (ja) |
| DE (1) | DE60223508T2 (ja) |
| DK (1) | DK1370264T3 (ja) |
| ES (1) | ES2295331T3 (ja) |
| IL (1) | IL157757A0 (ja) |
| MX (1) | MXPA03008423A (ja) |
| NO (1) | NO331674B1 (ja) |
| NZ (1) | NZ528042A (ja) |
| PL (1) | PL207880B1 (ja) |
| RU (1) | RU2299731C2 (ja) |
| WO (1) | WO2002076434A2 (ja) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| CA2341952A1 (en) | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| US20050130990A1 (en) * | 2001-03-23 | 2005-06-16 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US7045534B2 (en) * | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| US8557804B2 (en) | 2002-03-25 | 2013-10-15 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US8039459B2 (en) | 2004-07-15 | 2011-10-18 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US20040010018A1 (en) * | 2002-05-15 | 2004-01-15 | Rueter Lynne E. | Treatment of neuropathic pain |
| US7238715B2 (en) | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| PL364348A1 (en) | 2004-01-12 | 2005-07-25 | PHARMENA Sp.z o.o. | Application of quaternary pyridine salts as vessel protection agent |
| AU2005262174C1 (en) * | 2004-07-15 | 2010-05-06 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US9029557B2 (en) | 2004-12-07 | 2015-05-12 | The Regents Of The University Of California | Labeled A4B2 ligands and methods therefor |
| US8378109B2 (en) | 2004-12-07 | 2013-02-19 | The Regents Of The University Of California | Labeled ALPHA4BETA2 ligands and methods therefor |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| EP1978926A2 (en) * | 2005-12-19 | 2008-10-15 | Comentis, Inc. | Topical mecamylamine formulations for ocular administration and uses thereof |
| DK2801360T3 (en) * | 2006-05-08 | 2018-07-23 | Herrera Arturo Solis | Use of nicotine in the treatment of post-traumatic haemorrhage in humans |
| EP2549995B1 (en) * | 2010-03-23 | 2021-04-21 | Philip Morris Products S.A. | Use of anatabine to treat inflammation and methods of synthesizing anatabine |
| US8207346B2 (en) | 2010-03-23 | 2012-06-26 | Rock Creek Pharmaceuticals, Inc. | Methods of synthesizing anatabine |
| US20130053355A1 (en) | 2011-08-29 | 2013-02-28 | Rock Creek Pharmaceuticals, Inc. | Products for anti-inflammation support |
| WO2015149178A1 (en) | 2014-04-03 | 2015-10-08 | UNIVERSITé LAVAL | Method for use of homopiperazinium compounds in the treatment of cancer |
| RU2593585C1 (ru) * | 2015-06-26 | 2016-08-10 | Общество с ограниченной ответственностью "Ритек-Фарма" | Способ лечения табакокурения и других форм никотиновой зависимости, а также профилактики рецидивов табакокурения |
| CN113992687B (zh) * | 2021-12-28 | 2022-04-08 | 浙江宇视科技有限公司 | 智能业务集群调度方法、装置、电子设备及存储介质 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2594296A (en) * | 1948-06-24 | 1952-04-29 | Aerosol Corp | Lobeline aerosol dilating medicament |
| US2778772A (en) * | 1952-11-04 | 1957-01-22 | Parke Davis & Co | Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system |
| US3402039A (en) * | 1966-12-05 | 1968-09-17 | Dow Chemical Co | Piperazinium salts as plant stunting agents |
| US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| EP0791584A4 (en) * | 1994-11-11 | 1997-11-19 | Nippon Soda Co | OPTICALLY ACTIVE CONNECTIONS |
| WO2000023062A2 (en) | 1998-10-20 | 2000-04-27 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
| US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| RU2127123C1 (ru) * | 1996-06-04 | 1999-03-10 | Московское производственное химико-фармацевтическое объединение им.Н.А.Семашко | Противоастматическое лекарственное средство в виде таблеток и способ получения таблеток |
| GB9614902D0 (en) * | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| US5981549A (en) * | 1997-02-14 | 1999-11-09 | Synapse Pharmaceutical International | Method for controlling or alleviating the symptoms of respiratory disease and allergies |
| RU2205179C2 (ru) | 1997-10-27 | 2003-05-27 | НьюроСёрч А/С | Производное гомопиперазина и фармацевтическая композиция |
| JP2002538170A (ja) * | 1999-03-02 | 2002-11-12 | セントコール， インコーポレイテッド | 喘息の治療における抗−ＴＮＦα抗体 |
| EP1202738A4 (en) * | 1999-06-21 | 2002-08-14 | Bristol Myers Squibb Co | DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS |
| SE0001075D0 (sv) * | 1999-09-01 | 2000-03-27 | Laszlo Bense | Användning av åtminstone ett nikotinbaserat ämne och/eller ett ur detta ämne framställt ämne för tillverkning av ett medikament samt förfarande för behandling av obstruktiva lungsjukdomar |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| US6610713B2 (en) * | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| EP1339712B1 (en) | 2000-12-01 | 2008-02-06 | Neurosearch A/S | 3-substituted quinuclidines and their use as nicotinic agonists |
| US20020160988A1 (en) * | 2001-02-20 | 2002-10-31 | Israel Institute For Biological Research | Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof |
| JP2005501810A (ja) | 2001-03-22 | 2005-01-20 | バテル メモリアル インスティチュート | ポリマーおよび懸濁粒子を含有する電気流体力学的噴霧用の液体形成物 |
| US20050130990A1 (en) * | 2001-03-23 | 2005-06-16 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| CA2341952A1 (en) | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| GB2381750A (en) | 2001-10-10 | 2003-05-14 | Inspire Pharmaceuticals Inc | Treatment for enhancing joint lubrication |
| US20030236287A1 (en) * | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| TW200412945A (en) * | 2002-10-25 | 2004-08-01 | Upjohn Co | Quaternary ammonium compounds |
| JP2006506392A (ja) * | 2002-10-29 | 2006-02-23 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ムスカリン受容体アンタゴニストとしての第四級アンモニウム化合物 |
| AU2003267796A1 (en) * | 2002-10-29 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Quaternary ammonium compounds |
| US20050075323A1 (en) * | 2003-03-05 | 2005-04-07 | Pfizer Inc | Beta3 adrenergic receptor agonists and uses thereof |
| FR2852830B1 (fr) | 2003-03-24 | 2008-04-18 | Oreal | Composition de teinture des fibres keratiniques comprenant un derive de para-phenylenediamine cationique substitue par un cycle diazacyclohexane ou diazacycloheptane |
| BRPI0409370A (pt) * | 2003-04-15 | 2006-04-25 | Pharmacia & Upjohn Co Llc | compostos de amÈnio quaternário e seus usos como agentes antimuscarìnicos |
| AU2005262174C1 (en) | 2004-07-15 | 2010-05-06 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
-
2001
- 2001-03-23 CA CA002341952A patent/CA2341952A1/en not_active Abandoned
-
2002
- 2002-03-25 MX MXPA03008423A patent/MXPA03008423A/es active IP Right Grant
- 2002-03-25 RU RU2003131178/14A patent/RU2299731C2/ru not_active IP Right Cessation
- 2002-03-25 EP EP02717896A patent/EP1370264B1/en not_active Expired - Lifetime
- 2002-03-25 AU AU2002249023A patent/AU2002249023B2/en not_active Ceased
- 2002-03-25 DK DK02717896T patent/DK1370264T3/da active
- 2002-03-25 IL IL15775702A patent/IL157757A0/xx not_active IP Right Cessation
- 2002-03-25 WO PCT/CA2002/000412 patent/WO2002076434A2/en active IP Right Grant
- 2002-03-25 AT AT02717896T patent/ATE378051T1/de active
- 2002-03-25 US US10/469,999 patent/US7601720B2/en not_active Expired - Fee Related
- 2002-03-25 JP JP2002574950A patent/JP4377586B2/ja not_active Expired - Fee Related
- 2002-03-25 NZ NZ528042A patent/NZ528042A/en not_active IP Right Cessation
- 2002-03-25 PL PL365224A patent/PL207880B1/pl unknown
- 2002-03-25 ES ES02717896T patent/ES2295331T3/es not_active Expired - Lifetime
- 2002-03-25 BR BR0208305-1A patent/BR0208305A/pt not_active IP Right Cessation
- 2002-03-25 DE DE60223508T patent/DE60223508T2/de not_active Expired - Lifetime
- 2002-03-25 CN CNB028071387A patent/CN100528159C/zh not_active Expired - Fee Related
-
2003
- 2003-09-19 NO NO20034185A patent/NO331674B1/no not_active IP Right Cessation
-
2009
- 2009-09-03 US US12/553,574 patent/US20100227871A1/en not_active Abandoned
-
2011
- 2011-06-15 US US13/161,035 patent/US8377936B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2295331T3 (es) | 2008-04-16 |
| IL157757A0 (en) | 2004-03-28 |
| MXPA03008423A (es) | 2004-03-19 |
| EP1370264A2 (en) | 2003-12-17 |
| JP4377586B2 (ja) | 2009-12-02 |
| PL207880B1 (pl) | 2011-02-28 |
| NZ528042A (en) | 2005-10-28 |
| CN1498108A (zh) | 2004-05-19 |
| JP2004523588A (ja) | 2004-08-05 |
| US20100227871A1 (en) | 2010-09-09 |
| CA2341952A1 (en) | 2002-09-23 |
| ATE378051T1 (de) | 2007-11-15 |
| CN100528159C (zh) | 2009-08-19 |
| DE60223508T2 (de) | 2008-09-25 |
| US8377936B2 (en) | 2013-02-19 |
| NO20034185D0 (no) | 2003-09-19 |
| DK1370264T3 (da) | 2008-03-17 |
| BR0208305A (pt) | 2004-03-09 |
| WO2002076434A2 (en) | 2002-10-03 |
| EP1370264B1 (en) | 2007-11-14 |
| PL365224A1 (en) | 2004-12-27 |
| DE60223508D1 (de) | 2007-12-27 |
| RU2299731C2 (ru) | 2007-05-27 |
| US20040132737A1 (en) | 2004-07-08 |
| WO2002076434A3 (en) | 2003-07-17 |
| RU2003131178A (ru) | 2005-04-10 |
| NO20034185L (no) | 2003-11-24 |
| AU2002249023B2 (en) | 2006-02-02 |
| US20110245270A1 (en) | 2011-10-06 |
| US7601720B2 (en) | 2009-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO331674B1 (no) | Farmasoytisk sammensetning omfattende nikotinreseptorantagonist for lindring eller forebygging av pulmonaer inflammatorisk sykdom | |
| JP4954085B2 (ja) | 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト | |
| JPH08504745A (ja) | 自己免疫疾患のバイスタンダー抑制 | |
| US20070249622A1 (en) | Nicotinic receptor agonists and analogues and derivatives thereof for the treatment of inflammatory diseases | |
| JP2017533276A (ja) | 認知低下を処置するための方法 | |
| US11744829B2 (en) | Methods for treating neurological conditions and exposure to nerve agents | |
| AU2002249023A1 (en) | Nicotinic receptor agonists for the treatment of inflammatory diseases | |
| Wang et al. | Naltrexone attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in mice | |
| US20050148673A1 (en) | Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition | |
| Wei et al. | Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats | |
| TWI612961B (zh) | 類鐸受體４拮抗劑及於自體免疫肝臟疾病之用途 | |
| WO2014136118A1 (en) | Treatment of post-traumatic stress disorder with melanocortin receptor antagonist | |
| Zanardi et al. | Loss of high‐affinity nicotinic receptors increases the vulnerability to excitotoxic lesion and decreases the positive effects of an enriched environment | |
| WO2003053455A1 (en) | Surfactant prevention of lung complications from cancer chemotherapy | |
| Kline et al. | CpG oligodeoxynucleotides | |
| Webb | The Effects of Nicotine and Opioid Co-use on Dopaminergic and GABAergic Activity in the Ventral Tegmental Area | |
| US20230301985A1 (en) | Movement disorders | |
| US20220378769A1 (en) | Use of Glutamate 2B Receptor Antagonists and Sigma Receptor Agonists as Antitussives | |
| CA2441096C (en) | Nicotinic receptor agonists for the treatment of inflammatory diseases | |
| McDonald et al. | The Potential Role of Drug Onset Cues in Drug Dependence and Withdrawal: Reply to Bardo (2004), Bossert and Shaham (2004), Bouton (2004), and Stewart (2004). | |
| Bhanu Prakash et al. | INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES | |
| Reader | Social Stress Induces Immunoenhancement During Allergic Airway Inflammation and Infection | |
| EP1940376A2 (en) | Use of neboglamine in the treatment of toxicodependency | |
| US20110130425A1 (en) | Use of H3 Histaminergic Agonists for the Treatment of Addiction to Drugs of Abuse | |
| Hsia | The Role of Caveolin-1 and Surfactant Protein A as Regulators of Airway Hyperreactivity and Inflammation Following Innate Immune Challenges |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |